Table II.
Gene expression at mRNA level in tumor and non-tumor lung tissue [log2(ΔCq)] and the difference in the log-FC between the paired tissues [log2(FC)].
| mRNA level [log2(ΔCq)] | |||||
|---|---|---|---|---|---|
| Gene symbol | N | Tumor tissue Me (25–75%) | Normal lung tissue Me (25–75%) | P-value | Difference in mRNA level between tumor and normal lung tissues [log2(FC)] Me (25–75%) |
| VEGFC | 136 | 17.67 (16.33–18.54) | 16.58 (15.39–17.84) | <0.0001 | −0.92 (−1.88–0.06) |
| VEGFD | 136 | 18.75 (16.37–21.74) | 15.57 (14.27–16.55) | <0.0001 | −2.72 -(5.92–0.61) |
| VEGFR3 | 136 | 18.72 (17.65–19.53) | 17.39 (16.79–18.27) | <0.0001 | −0.89 -(1.95–0.16) |
| LYVE1 | 136 | 18.91 (17.15–20.23) | 16.69 (15.31–17.68) | <0.0001 | −2.08 -(3.37–0.48) |
| ITGA9 | 136 | 16.06 (15.16–17.34) | 15.43 (14.45–16.22) | <0.0001 | −1.02 (−1.86–0.14) |
| PDPN | 136 | 15.71 (14.45–16.96) | 15.75 (14.50–16.81) | 0.640 | −0.13 (−1.15–1.30) |
| DSP | 137 | 13.81 (11.93–15.59) | 16.66 (15.12–17.52) | <0.0001 | 2.58 (0.44–4.39) |
| PROX1 | 136 | 20.53 (18.27–21.80) | 20.47 (18.95–22.09) | 0.611 | 0.17 (−1.21–1.70) |
| FOXC1 | 136 | 15.27 (14.04–16.44) | 13.96 (13.06–15.03) | 0.0003 | −1.45 (−2.29–0.41) |
| NRP2 | 136 | 14.16 (12.78–15.29) | 13.97 (12.61–14.99) | 0.021 | −0.16 (−1.12–0.55) |
| VEGFA | 136 | 13.34 (11.86–14.77) | 13.37 (11.97–14.76) | 0.861 | 0.03 (−0.81–0.80) |
| FGF2 | 137 | 19.57 (17.46–20.50) | 18.05 (16.86–19.05) | 0.0002 | −1.10 (−2.41–0.24) |
| VEGFR1 | 136 | 16.99 (15.48–18.40) | 16.83 (14.73–17.42) | 0.0002 | −0.92 -(1.78–0.15) |
| VEGFR2 | 136 | 16.13 (14.65–17.85) | 15.11 (13.63–16.56) | <0.0001 | −1.16 (−2.18–0.10) |
| SYK | 138 | 16.27 (15.28–17.40) | 16.16 (15.02–17.50) | 0.387 | −0.30 (−1.11–1.61) |
FC, fold-change; VEGF, vascular endothelial growth factor; LYVE1, lymphatic vessel hyaluronan receptor 1; ITGA9, integrin a9; PDPN, podoplanin; DSP, desmoplakin; PROX1, prospero-related homeobox domain 1; FOXC1, Forkhead box C1; NRP2, neuropilin 2; FGF2, fibroblast growth factor 2; SYK, spleen protein kinase.